Back to mobile site

Jazz Pharmaceuticals (JAZZ) PT Raised to $258 at RBC Capital

May 6, 2026 5:24 AM EDT Send to a Friend
RBC Capital analyst Leonid Timashev raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $258.00 (from $195.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login